Biogen’s $7.3 Bln acquisition of Reata followed bidding warBiogen’s $7.3 billion acquisition of Reata Pharmaceuticals — its first major deal in more than four years — came after a showdown with another potential buyer and saw the acquisition price pushed up from $140 a share to $172.50, according to a securities filing.
https://endpts.com/biogens-7-3b-deal-for-reata-came-after-outbidding-mysterious-party-a/